- Home
- ATHA vs TENX Comparison
ATHA vs TENX Comparison
Compare ATHA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- TENX
- Stock Information
- Founded
- ATHA 2011
- TENX 1967
- Country
- ATHA United States
- TENX United States
- Employees
- ATHA N/A
- TENX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- TENX Health Care
- Exchange
- ATHA Nasdaq
- TENX Nasdaq
- Market Cap
- ATHA 21.0M
- TENX 21.6M
- IPO Year
- ATHA 2020
- TENX N/A
- Fundamental
- Price
- ATHA $0.26
- TENX $5.56
- Analyst Decision
- ATHA Buy
- TENX Strong Buy
- Analyst Count
- ATHA 4
- TENX 3
- Target Price
- ATHA $11.25
- TENX $16.00
- AVG Volume (30 Days)
- ATHA 204.2K
- TENX 13.0K
- Earning Date
- ATHA 05-14-2025
- TENX 05-20-2025
- Dividend Yield
- ATHA N/A
- TENX N/A
- EPS Growth
- ATHA N/A
- TENX N/A
- EPS
- ATHA N/A
- TENX N/A
- Revenue
- ATHA N/A
- TENX N/A
- Revenue This Year
- ATHA N/A
- TENX N/A
- Revenue Next Year
- ATHA N/A
- TENX N/A
- P/E Ratio
- ATHA N/A
- TENX N/A
- Revenue Growth
- ATHA N/A
- TENX N/A
- 52 Week Low
- ATHA $0.22
- TENX $2.77
- 52 Week High
- ATHA $3.67
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- ATHA 42.81
- TENX 51.64
- Support Level
- ATHA $0.23
- TENX $5.49
- Resistance Level
- ATHA $0.27
- TENX $5.87
- Average True Range (ATR)
- ATHA 0.03
- TENX 0.33
- MACD
- ATHA 0.00
- TENX 0.04
- Stochastic Oscillator
- ATHA 27.53
- TENX 84.80
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.